Dr. Daniel Esmaili, M.D.
What this data tells you about Dr. Esmaili
Dr. Daniel Esmaili is an ophthalmology specialist in Beverly Hills, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Esmaili performed 21,634 Medicare services across 3,617 unique beneficiaries.
Between the years covered by Open Payments, Dr. Esmaili received a total of $46,877 from 9 pharmaceutical and/or device companies across 68 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Esmaili is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Eye injection (Vabysmo/faricimab) An injection of faricimab-svoa, a medication administered in 0.1 mg doses. |
8,220 | $29 | $83 |
| Retinal imaging (OCT scan) This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye. |
3,155 | $35 | $152 |
| Comprehensive eye exam, established patient A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider. |
2,212 | $104 | $273 |
| Aflibercept eye injection (Eylea) | 1,978 | $688 | $2,319 |
| Eye injection for retinal disease A procedure involving the administration of medication directly into the eye. |
1,952 | $103 | $814 |
| Ranibizumab-eqrn injection, 0.1 mg An injection of the biosimilar medication ranibizumab-eqrn (Cimerli) in a 0.1 mg dose. |
1,508 | $218 | $700 |
| Eye exam, established patient, focused A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom. |
668 | $80 | $193 |
| Bevacizumab injection, 10 mg Administration of a 10 mg dose of bevacizumab medication via injection. |
530 | $57 | $170 |
| Extended eye exam with retinal drawing A detailed examination of the back of the eye that includes creating a drawing of the retina. |
384 | $18 | $158 |
| Pegcetacoplan intravitreal injection, 1 mg An injection of pegcetacoplan administered into the vitreous humor of the eye. The dose specified is 1 milligram. |
330 | $120 | $363 |
| Extended exam of back of eye with optic nerve drawing A detailed examination of the posterior section of the eye, including the optic nerve, with documentation through drawing. |
260 | $12 | $162 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
219 | $131 | $295 |
| Ultrasound of eye tissue and structures A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures. |
67 | $39 | $234 |
| Retinal angiography with dye injection This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body. |
65 | $123 | $291 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
65 | $1,444 | $4,369 |
| Retinal photography (fundus photo) This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures. |
21 | $32 | $115 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
All-time payments by company (2018-2024) ›
Associated products mentioned in payments ›
The majority of payments (77%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in ophthalmology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 7% for ophthalmology in CA.
Geographic Context
0.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Esmaili is a mixed practice specialist, with above-average Medicare volume (top 5% in CA), with speaking/promotional industry engagement in the top 7% of CA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Esmaili experienced with eye injection (vabysmo/faricimab)?
Does Dr. Esmaili receive payments from pharmaceutical companies?
How do Dr. Esmaili's costs compare to other ophthalmologists in Beverly Hills?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology